The primary rationale for improving in vivo BDNF levels in patients with neurodegenerative conditions such as AD, HD, and MS is to safeguard the brain against substantial structural alterations when exposed to the non-conducive, neurodegenerative environment associated with the disease. The gene discussed is BDNF; the disease is myeloid sarcoma.